

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

## EP Clinical Conferences -Post Operative AF – 58249-58177

Date: April 21, 2023

Time: 7:30 AM-8:30 AM

*Jayakumar Sahadevan, MD; Seungyup Lee, PhD*  
*Case Western Reserve University*

### Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify and apply the principles of quality and safety to their practice
- 2 Critically analyze research, guidelines and appropriate use criteria to develop best-practice diagnosis and treatment strategies
- 3 Evaluate latest innovations in the management and treatment of cardiovascular disease to assess safety and effectiveness

### Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Sanjay Rajagopalan, MD	Course Director	Consulting Fee-Novo Nordisk - 08/29/2022
Seungyup Lee, PhD	Faculty	Nothing to disclose - 09/14/2022
Jayakumar Sahadevan, MD	Faculty	Nothing to disclose - 08/10/2022
Janice Friswold, Ms.	Other Planning Committee Member	Nothing to disclose - 09/14/2022
Diane Gorbey, RN, CNS	Other Planning Committee Member	Nothing to disclose - 02/20/2023
Judith Mackall, MD	Other Planning Committee Member	Consulting Fee-Abbott Laboratories - 08/29/2022
Ian J Neeland, MD	Other Planning Committee Member	Consulting Fee-Merck and Company, Inc. (Relationship has ended) Consulting Fee-Boehringer Ingelheim Consulting Fee-Nestle Health Sciences Consulting Fee-Bayer Corporation - 02/28/2023